This study aimed to compare possible differences in the serum podoplanin concentration between patients with angiographically proven de novo coronary artery disease and a control group (patients with normal coronary angiograms) to assess its potential as a CAD biomarker. The gene discussed is PDPN; the disease is coronary artery disorder.